Stock Analysis, Dividends, Split History
WG / Willbros Group, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.
|Market Cap ($M)||9.80|
|Enterprise Value ($M)||245.19|
|Book Value ($M)||15.17|
|Book Value / Share||0.24|
|Price / Book||0.65|
|NCAV / Share||-2.02|
|Price / NCAV||-0.08|
|Income Statement (mra) ($M)|
|Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price||2,000,000.00|
|Disposal Group Including Discontinued Operation Revenue||0.00|
|Earnings Per Share Diluted||-1.74|
|Earnings Per Share Basic||-1.74|
|Cash Flow Statement (mra) ($M)|
|Cash From Operations||-51.47|
|Cash from Investing||2.58|
|Cash from Financing||2.58|
|Identifiers and Descriptors|
|Central Index Key (CIK)||1449732|
|969199108 969203908 969203958|
|SIC 1389 - Oil and Gas Field Services, Not Elsewhere Classified|
Stock splits are used by Willbros Group, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.
9h - Asif
Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...
9h - Asif
Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...
10h - Asif
General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...
Related News Stories
CCT remains underleveraged and reported March 31 results just below my base case projections mostly due to lower-than-expected fee income but still covered its dividend by 97%. (37-3)
Sum of the parts and peer comps suggests 50%+ of value is due to its new T&D infrastructure business. (22-0)
The Texas-based vice-president of a company hoping to bid on Canadian pipeline projects wants to stop a hearing that could see him barred from crossing the border because of a past conviction for bribery. (13-0)
Primoris Services Corporation (PRIM - Free Report) recently entered into a definitive merger agreement to acquire Willbros Group, Inc. — a specialty energy infrastructure contractor — for an enterprise value of about $100 million. The buyout will strengthen Primoris’ business and boost revenues as well as profitability. About Willbros Headquartered in Houston, TX, Willbros serves the oil & gas and power industries through three operating segments — Utility Transmission and Distribution (“UTD”), Oil & Gas and Canada. (7-0)
* WILLBROS GROUP SAYS UPON TERMINATION OF MERGER IN CERTAIN CIRCUMSTANCES, CO TO PAY PRIMORIS FEE OF $4.3 MILLION - SEC FILING (7-1)
Silicon Investor Message Boards
This table lists all message boards related to WG / Willbros Group, Inc. on message board site Silicon Investor.
as of ET